硫唑嘌呤治疗免疫相关性皮肤病专家建议

doi:10.35541/cjd.20200469

中华皮肤科杂志 ›› 2021, Vol. 54 ›› Issue (2): 116-121.doi: 10.35541/cjd.20200469

硫唑嘌呤治疗免疫相关性皮肤病专家建议

中国医师协会皮肤科医师分会自身免疫病专业委员会

中国医师协会皮肤科医师分会自身免疫病专业委员会

收稿日期:2020-05-14 修回日期:2020-08-24 发布日期:2021-01-29
通讯作者: 邓丹琪 E-mail:danqid128@sina.com

Azathioprine in the treatment of immune?related skin diseases: an expert proposal

Committee on Autoimmune Diseases, China Dermatologist Association

Committee on Autoimmune Diseases, China Dermatologist Association

Received:2020-05-14 Revised:2020-08-24 Published:2021-01-29
Contact: Deng Danqi E-mail:danqid128@sina.com

摘要/Abstract

摘要： 【摘要】硫唑嘌呤系巯嘌呤的咪唑衍生物，广泛用于自身免疫性疾病的治疗。为了规范硫唑嘌呤在皮肤科的正确应用，中国医师协会皮肤科医师分会自身免疫病专业委员会相关专家在检索和研究国内外硫唑嘌呤治疗免疫相关性疾病相关文献（主要是随机对照临床试验、专家共识或专家建议）的基础上，经反复讨论，提出硫唑嘌呤在免疫性大疱性皮肤病、皮肤血管炎、系统性红斑狼疮、皮肌炎、硬皮病等免疫性皮肤病治疗中的建议，分析硫唑嘌呤与其他药物的相互作用以及使用中的注意事项。

关键词: 硫唑嘌呤, 治疗, 自身免疫疾病, 结缔组织疾病, 天疱疮, 红斑狼疮, 系统性, 皮肌炎

Abstract: 【Abstract】 Azathioprine, an imidazole derivative of mercaptopurine, has been widely used in the treatment of autoimmune diseases. In order to standardize the application of azathioprine in dermatology, relevant experts in the Committee on Autoimmune Diseases of China Dermatologist Association searched and studied domestic and foreign literature on azathioprine for the treatment of immune-related diseases （mainly including randomized control trials, expert consensus or proposals）, and proposed a proposal after repeated discussions for azathioprine in the treatment of immune skin diseases, including immune bullous skin diseases, cutaneous vasculitis, systemic lupus erythematosus, dermatomyositis, scleroderma, etc. Interactions between azathioprine and other drugs, as well as issues needed to be considered in its application were also analyzed in this proposal.

Key words: Azathioprine, Therapy, Autoimmune diseases, Connective tissue diseases, Pemphigus, Lupus erythematosus, systemic, Dermatomyositis

中国医师协会皮肤科医师分会自身免疫病专业委员会. 硫唑嘌呤治疗免疫相关性皮肤病专家建议[J]. 中华皮肤科杂志, 2021,54(2):116-121. doi:10.35541/cjd.20200469

Committee on Autoimmune Diseases, China Dermatologist Association. Azathioprine in the treatment of immune?related skin diseases: an expert proposal[J]. Chinese Journal of Dermatology, 2021, 54(2): 116-121.doi:10.35541/cjd.20200469

参考文献 37

［1］	Wollenberg A, Szepietowski J, Taieb A, et al. Corrigendum: Consensus⁃based European guidelines for treatment of atopic eczema （atopic dermatitis） in adults and children: part I［J］. J Eur Acad Dermatol Venereol, 2019,33（7）:1436. doi: 10.1111/jdv.15719.
［2］	Paek SY, Lim HW. Chronic actinic dermatitis［J］. Dermatol Clin,2014,32（3）:355⁃361, viii⁃ix. doi: 10.1016/j.det.2014.03.007.
［3］	Verma P, Verma KK, Khanna N, et al. Effectiveness of weekly azathioprine pulse in the treatment of chronic plaque psoriasis: an open⁃label study［J］. Clin Exp Dermatol, 2016,41（7）:717⁃722. doi: 10.1111/ced.12887.
［4］	Engelmann C, Elsner P, Miguel D. Treatment of pityriasis rubra pilaris type I: a systematic review［J］. Eur J Dermatol, 2019,29（5）:524⁃537. doi: 10.1684/ejd.2019.3641.
［5］	Tal Y, Toker O, Agmon⁃Levin N, et al. Azathioprine as a therapeutic alternative for refractory chronic urticaria［J］. Int J Dermatol, 2015,54（3）:367⁃369. doi: 10.1111/ijd.12536.
［6］	Relling MV, Schwab M, Whirl⁃Carrillo M, et al. Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update［J］. Clin Pharmacol Ther, 2019,105（5）:1095⁃1105. doi: 10.1002/cpt.1304.
［7］	Rucci F, Cigoli MS, Marini V, et al. Combined evaluation of genotype and phenotype of thiopurine S⁃methyltransferase （TPMT） in the clinical management of patients in chronic therapy with azathioprine［J/OL］. Drug Metab Pers Ther, 2019,34（1）［2020⁃03⁃19］. http://www.metstr.com. doi: 10.1515/dmpt⁃2018⁃0037.
［8］	Wilson A, Jansen LE, Rose RV, et al. HLA⁃DQA1⁃HLA⁃DRB1 polymorphism is a major predictor of azathioprine⁃induced pancreatitis in patients with inflammatory bowel disease［J］. Aliment Pharmacol Ther, 2018,47（5）:615⁃620. doi: 10.1111/apt. 14483.
［9］	Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines［J］. BMJ, 2001,323（7308）:334⁃336. doi: 10.1136/bmj.323.7308.334.
［10］	Hertl M, Jedlickova H, Karpati S, et al. Pemphigus. S2 Guideline for diagnosis and treatment⁃⁃guided by the European Dermatology Forum （EDF） in cooperation with the European Academy of Dermatology and Venereology （EADV）［J］. J Eur Acad Dermatol Venereol, 2015,29（3）:405⁃414. doi: 10.1111/jdv. 12772.
［11］	Committee for Guidelines for the Management of Pemphigus Disease, Amagai M, Tanikawa A, et al. Japanese guidelines for the management of pemphigus［J］. J Dermatol, 2014,41（6）:471⁃486. doi: 10.1111/1346⁃8138.12486.
［12］	Yanovsky RL, McLeod M, Ahmed AR. Treatment of pemphigus vulgaris: part 1 ⁃ current therapies［J］. Expert Rev Clin Immunol, 2019,15（10）:1047⁃1060. doi: 10.1080/1744666X.2020.1672535.
［13］	Sticherling M, Franke A, Aberer E, et al. An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone［J］. Br J Dermatol, 2017,177（5）:1299⁃1305. doi: 10.1111/bjd.15649.
［14］	Feliciani C, Joly P, Jonkman MF, et al. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology［J］. Br J Dermatol, 2015,172（4）:867⁃877. doi: 10. 1111/bjd.13717.
［15］	Porro AM, Hans Filho G, Santi CG. Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus ⁃ Brazilian Society of Dermatology［J］. An Bras Dermatol, 2019,94（2 Suppl 1）:20⁃32. doi: 10.1590/abd1806⁃ 4841.2019940206.
［16］	Yoshida A, Watanabe M, Okubo A, et al. Clinical characteristics of scleritis patients with emphasized comparison of associated systemic diseases （anti⁃neutrophil cytoplasmic antibody⁃associated vasculitis and rheumatoid arthritis）［J］. Jpn J Ophthalmol, 2019,63（5）:417⁃424. doi: 10.1007/s10384⁃019⁃00674⁃7.
［17］	中国狼疮肾炎诊断和治疗指南编写组. 中国狼疮肾炎诊断和治疗指南［J］. 中华医学杂志, 2019,99（44）:3441⁃3455. doi: 10.3760/cma.j.issn.0376⁃2491.2019.44.001.
［18］	Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association⁃European Dialysis and Transplant Association （EULAR/ERA⁃EDTA） recommendations for the management of adult and paediatric lupus nephritis［J］. Ann Rheum Dis, 2012,71（11）:1771⁃1782. doi: 10.1136/annrheumdis⁃2012⁃201940.
［19］	Parikh SV, Rovin BH. Current and emerging therapies for lupus nephritis［J］. J Am Soc Nephrol, 2016,27（10）:2929⁃2939. doi: 10.1681/ASN.2016040415.
［20］	Ordi⁃Ros J, Sáez⁃Comet L, Pérez⁃Conesa M, et al. Enteric⁃coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial［J］. Ann Rheum Dis, 2017,76（9）:1575⁃1582. doi: 10.1136/annrheumdis⁃2016⁃210882.
［21］	Pons⁃Estel BA, Bonfa E, Soriano ER, et al. First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus （GLADEL, Grupo Latino Americano de Estudio del Lupus）⁃Pan⁃American League of Associations of Rheumatology （PANLAR）［J］. Ann Rheum Dis, 2018,77（11）:1549⁃1557. doi: 10.1136/annrheumdis⁃2018⁃213512.
［22］	Tamirou F, D′Cruz D, Sangle S, et al. Long⁃term follow⁃up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis［J］. Ann Rheum Dis, 2016,75（3）:526⁃531. doi: 10.1136/annrheumdis⁃2014⁃206897.
［23］	Dalakas MC. Inflammatory myopathies: management of steroid resistance［J］. Curr Opin Neurol, 2011,24（5）:457⁃462. doi: 10. 1097/WCO.0b013e32834a9589.
［24］	Kohsaka H, Mimori T, Kanda T, et al. Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists［J］. J Dermatol, 2019,46（1）:e1⁃e18. doi: 10.1111/1346⁃8138.14604.
［25］	中华医学会儿科学分会免疫学组, 《中华儿科杂志》编辑委员会, 胡坚. 幼年皮肌炎诊治建议［J］. 中华儿科杂志, 2012,50（8）:617⁃621. doi: 10.3760/cma.j.issn.0578⁃1310.2012.08.013.
［26］	Bérezné A, Ranque B, Valeyre D, et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open⁃label study［J］. J Rheumatol, 2008,35（6）:1064⁃1072.
［27］	Iudici M, Cuomo G, Vettori S, et al. Low⁃dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis （SSc⁃ILD）: efficacy of maintenance immunosuppression in responders and non⁃responders［J］. Semin Arthritis Rheum, 2015, 44（4）:437⁃444. doi: 10.1016/j.semarthrit.2014.09.003.
［28］	Schram ME, Roekevisch E, Leeflang MM, et al. A randomized trial of methotrexate versus azathioprine for severe atopic eczema［J］. J Allergy Clin Immunol, 2011,128（2）:353⁃359. doi: 10. 1016/j.jaci.2011.03.024.
［29］	Sarika S, Criton S. Effectiveness of weekly azathioprine pulse in the treatment of chronic plaque psoriasis: an open⁃label study: reply to author［J］. Clin Exp Dermatol, 2017,42（7）:805⁃806. doi: 10.1111/ced.13193.
［30］	Solman L, Lloyd⁃Lavery A, Grindlay DJC, et al. What′s new in atopic eczema? An analysis of systematic reviews published in 2016. Part 1: treatment and prevention［J］. Clin Exp Dermatol, 2019,44（4）:363⁃369. doi:10.1111/ced.13885.
［31］	Paek SY, Lim HW. Chronic actinic dermatitis［J］. Dermatol Clin, 2014,32（3）:355⁃361, viii⁃ix. doi: 10.1016/j.det.2014.03.007.
［32］	Sunderkötter C, Nast A, Worm M, et al. Guidelines on dermatomyositis⁃⁃excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology［J］. J Dtsch Dermatol Ges, 2016,14（3）:321⁃338. doi: 10.1111/ddg.12909.
［33］	Mathur T, Manadan AM, Thiagarajan S, et al. Corticosteroid monotherapy is usually insufficient treatment for idiopathic inflammatory myopathy［J］. Am J Ther, 2015,22（5）:350⁃354. doi: 10.1097/MJT.0b013e3182987983.
［34］	Relling MV, Gardner EE, Sandborn WJ, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther, 2011,89（3）:387⁃391. doi: 10.1038/clpt. 2010.320.
［35］	Yang J, Wang P, Qin Z, et al. NUDT15 and TPMT genetic polymorphisms are related to azathioprine intolerance in Chinese patients with rheumatic diseases［J］. Genet Test Mol Biomarkers, 2019,23（10）:751⁃757. doi: 10.1089/gtmb.2018.0313.
［36］	Kim HT, Choi R, Won HH, et al. NUDT15 genotype distributions in the Korean population［J］. Pharmacogenet Genomics, 2017,27（5）:197⁃200. doi: 10.1097/FPC.000000000 0000274.
［37］	Tanaka Y, Kato M, Hasegawa D, et al. Susceptibility to 6⁃MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia［J］. Br J Haematol, 2015, 171（1）:109⁃115. doi: 10.1111/bjh.13518.

[1]	侯晓媛吴南辉徐明圆刘业强. JAK抑制剂巴瑞替尼治疗环状肉芽肿1例[J]. 中华皮肤科杂志, 2024, 57(5): 461-462.
[2]	罗帅寒天龙海陆前进, . 2023年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2024, 57(5): 468-471.
[3]	《乳房外Paget病诊治专家共识（版）》编写委员会专家组. [开放获取] 乳房外Paget病诊治专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 400-408.
[4]	中国医师协会皮肤科医师分会. [开放获取] 慢性瘙痒管理指南（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 387-399.
[5]	中国“一带一路”皮肤病专病联盟分枝杆菌病研究联盟中国麻风防治协会皮肤性病检验与诊断分会. [开放获取] 中国皮肤结核临床诊疗专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 426-434.
[6]	中国医师协会皮肤科医师分会中国中西医结合学会皮肤性病学分会. 红皮病型银屑病诊疗中国专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 409-417.
[7]	中国中西医结合学会皮肤性病学分会真菌学组中国耐药皮肤癣菌病诊治与防控工作组. [开放获取] 中国耐药皮肤癣菌感染诊治与防控专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 418-425.
[8]	岳淑珍树叶罗鸯鸯李珂瑶张圆圆汤建萍韦祝. 奥马珠单抗治疗儿童慢性荨麻疹的疗效和安全性回顾研究[J]. 中华皮肤科杂志, 2024, 57(4): 354-358.
[9]	葛新红马迎东焦亚宁刘玲玲周镁紫薇李博文. 532 nm皮秒激光治疗面部早期脂溢性角化病的疗效和安全性分析[J]. 中华皮肤科杂志, 2024, 57(4): 359-362.
[10]	刘祎曲莹雷文知刘晓刚潘炜华张超. 食盐封包法治疗化脓性肉芽肿25例临床观察[J]. 中华皮肤科杂志, 2024, 0(4): 20230553-e20230553.
[11]	鞠强李嘉祺. [开放获取] 寻常痤疮再认识：从发病机制到治疗策略[J]. 中华皮肤科杂志, 2024, 57(4): 289-294.
[12]	张迪敏曹成周妙妮盛安琪林福全许爱娥. 复方倍他米松注射液联合治疗后进展期非节段型白癜风稳定率及影响因素分析[J]. 中华皮肤科杂志, 2024, 57(4): 350-354.
[13]	田静邓思思宋志强. 特应性与非特应性结节性痒疹患者临床特征比较[J]. 中华皮肤科杂志, 2024, 57(4): 331-337.
[14]	严汝帆廖洁月郭子瑜姚南周文玉罗帅寒天张桂英赵明. 天疱疮发病机制和靶向治疗的研究进展[J]. 中华皮肤科杂志, 2024, 57(4): 374-378.
[15]	宋雨晴杨楠刘琳琳冯子仪韩世新周梅娟. [开放获取] 皮肤磨削术治疗家族性良性慢性天疱疮6例临床观察[J]. 中华皮肤科杂志, 2024, 0(4): 20220278-e20220278.

硫唑嘌呤治疗免疫相关性皮肤病专家建议

Azathioprine in the treatment of immune?related skin diseases: an expert proposal

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 37

相关文章 15

Metrics

本文评价

推荐阅读 10